![]() After the COMPARE trial period of 3 years, study subjects chose to continue their losartan medication or not. In the original COMPARE study (inclusion 2008-2009), adult patients with MFS (n = 233) were randomly allocated to either the angiotensin-II receptor blocker losartan® on top of regular treatment (β-blockers in 71% of the patients) or no additional medication. The aim of the current study was therefore to investigate the long-term clinical outcomes after losartan treatment. However, no significant effect was found on clinical endpoints, possibly due to a short follow-up period. The COMPARE trial showed a small but significant beneficial effect of 3-year losartan treatment on aortic root dilatation rate in adults with Marfan syndrome (MFS). 8 Department of Radiology, Amsterdam UMC, University of Amsterdam, MeibergdrAZ Amsterdam, the Netherlands.7 Department of Medical Biochemistry, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, MeibergdrAZ, Amsterdam, The Netherlands.6 Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam UMC, University of Amsterdam, MeibergdrAZ, Amsterdam, The Netherlands.5 Department of Cardiology, University Medical Center Groningen, HanzeplGZ Groningen, The Netherlands.4 Department of Cardiology, Leiden University Medical Center, AlbinusdrAZ, Leiden, The Netherlands.Radboud University Medical Center, Geert grooteplGA, Nijmegen, The Netherlands. 2 Department of Vascular Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, MeibergdrAZ, Amsterdam, The Netherlands.1 Department of Cardiology, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, MeibergdrAZ, Amsterdam, The Netherlands. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |